Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 929-932

  Rago, Angela ^a   Lichtner, Miriam ^a   Mecarocci, Sergio ^a   Marocco, Raffaella ^a   Cenfra, Natalia ^a   Belvisi, Valeria ^a   Del Borgo, Cosmo ^b   Cimino, Giuseppe ^a   Mastroianni, Claudio M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; RITUXIMAB; TENOFOVIR DISOPROXIL;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; VIRUS REACTIVATION;

ADENINE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PHOSPHONIC ACIDS; VIRUS ACTIVATION;

EID: 77957372602     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1633     Document Type: Article

References (18)

1. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008; 2:152-162.
2. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89:255-262.
3. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4:599-610.
4. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alentuzumab therapy. Eur J Haematol 2005; 74:254-258.
5. Aksoy S, Harputluoglu H, Kilckap S, et al. Rituximab related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48:1307-1312.
6. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136:699-712.
7. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113:3147-3153.
8. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90:13-23.
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
10. Francisci D, Falcinelli F, Schiaroli E, et al. Management of hepatitis B virus reactivation in patients with haematological malignancies treated with chemotherapy. Infection 2010; 38:58-61.
11. Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009; 50:461-470.
12. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009; 18:1655-1666.
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
14. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007; 85:16-23.
15. Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26 Suppl 48:S39-S47.
16. Soza A, Lau DT, Khokhar MF, Conjeevaram H, Park Y, Hoofnagle JH. Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy. J Pediatr Gastroenterol Nutr 2003; 36:141-143.
17. Colson P, Borentain P, Coso D, Chabannon C, Tamalet C, Gérolami R. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143:148-150.
18. Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51:1091-1096.